Publications

A systematic analysis of the human immune response to Plasmodium vivax

Bach FA. et al, (2023), Journal of Clinical Investigation

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Mentzer AJ. et al, (2022), Nature Medicine

Impact of a blood-stage vaccine on Plasmodium vivax malaria

Hou MM. et al, (2022)

Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly

Minassian AM. et al, (2021), JCI Insight, 6

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum

Milne K. et al, (2021), eLife, 10

Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen N. et al, (2021), Nature, 590, E24 - E24

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen N. et al, (2020), Nature, 586, 578 - 582

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques

van Doremalen N. et al, (2020), Science Advances, 6

A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates

Douglas AD. et al, (2019), Nature Communications, 10

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

Rampling T. et al, (2018), npj Vaccines, 3

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

Payne RO. et al, (2017), JCI Insight, 2

SAFETY AND IMMUNOGENICITY OF THE NOVEL PLASMODIUM FALCIPARUM BLOOD-STAGE VACCINE CHAD63-MVA RH5 IN A PHASE IA CLINICAL TRIAL

Payne R. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 95, 313 - 313

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies

Payne RO. et al, (2017), JCI Insight, 2

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

Bliss CM. et al, (2017), Molecular Therapy, 25, 547 - 559

Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts

Churcher TS. et al, (2017), PLOS Pathogens, 13, e1006108 - e1006108

HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT

Venkatraman N. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 97, 594 - 594

PROBABILITY OF TRANSMISSION OF MALARIA FROM MOSQUITO TO HUMAN IS REGULATED BY PARASITE DENSITY IN NAIVE AND VACCINATED HOSTS

Churcher TS. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 97, 230 - 230

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

Mensah VA. et al, (2016), PLOS ONE, 11, e0167951 - e0167951

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

Rampling T. et al, (2016), Journal of Infectious Diseases, 214, 772 - 781

Demonstration of the Blood-StagePlasmodium falciparumControlled Human Malaria Infection Model to Assess Efficacy of theP. falciparumApical Membrane Antigen 1 Vaccine, FMP2.1/AS01

Payne RO. et al, (2016), Journal of Infectious Diseases, 213, 1743 - 1751

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

Ewer K. et al, (2016), New England Journal of Medicine, 374, 1635 - 1646

Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies

Hodgson SH. et al, (2015), Malaria Journal, 14

Assessment of FMP2.1/AS01B, an asexual blood-stage malaria vaccine, in a phase I/II a clinical trial using blood-stage controlled human malaria infection

Payne RO. et al, (2015), TROPICAL MEDICINE & INTERNATIONAL HEALTH, 20, 22 - 22

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

Ogwang C. et al, (2015), Science Translational Medicine, 7

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals

Hodgson SH. et al, (2015), Journal of Infectious Diseases, 211, 1076 - 1086

Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations

Kimani D. et al, (2014), Molecular Therapy, 22, 1992 - 2003

Correction for Nébié et al., Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors

Nébié I. et al, (2014), Clinical and Vaccine Immunology, 21, 1376 - 1376

Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors

Nébié I. et al, (2014), Clinical and Vaccine Immunology, 21, 901 - 903

External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance

Murphy SC. et al, (2014), PLoS ONE, 9, e97398 - e97398

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

Ewer KJ. et al, (2013), Nature Communications, 4

Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection

Douglas AD. et al, (2013), The Journal of Infectious Diseases, 208, 340 - 345

Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe

Sheehy SH. et al, (2013), PLoS ONE, 8, e65960 - e65960

Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques

White AD. et al, (2013), Clinical and Vaccine Immunology, 20, 663 - 672

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

Sheehy SH. et al, (2012), Molecular Therapy, 20, 2355 - 2368

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

Dicks MDJ. et al, (2012), PLoS ONE, 7, e40385 - e40385

Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials

Roestenberg M. et al, (2012), PLoS ONE, 7, e38434 - e38434

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

O’Hara GA. et al, (2012), The Journal of Infectious Diseases, 205, 772 - 781

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

Sheehy SH. et al, (2012), PLoS ONE, 7, e31208 - e31208

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans

Sheehy SH. et al, (2012), Molecular Therapy, 20, 2355 - 2368

Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909

Duncan CJA. et al, (2011), PLoS ONE, 6, e22271 - e22271

Cloning and characterization of hIF2, a human homologue of bacterial translation initiation factor 2, and its interaction with HIV-1 matrix

WILSON SA. et al, (1999), Biochemical Journal, 342, 97 - 97

Cookies on this website

Publications